LRP1 and bladder transitional cell carcinoma: Along with the prediction by TIDE algorithm and the validation by IMvigor210 cohort, our findings indicated that BLCA with high LRP1 expression tended to have lower responsiveness to immune checkpoint blockade therapy, highlighting the involvement of LRP1 expressing CAFs and macrophages in affecting the responsiveness of BLCA patients to ICB therapy.